Radiotherapy-Related Dose and Irradiated Volume Effects on Breast Cancer Risk Among Hodgkin Lymphoma Survivors.
Journal
Journal of the National Cancer Institute
ISSN: 1460-2105
Titre abrégé: J Natl Cancer Inst
Pays: United States
ID NLM: 7503089
Informations de publication
Date de publication:
09 09 2022
09 09 2022
Historique:
received:
08
02
2022
revised:
05
05
2022
accepted:
24
06
2022
pubmed:
1
7
2022
medline:
15
9
2022
entrez:
30
6
2022
Statut:
ppublish
Résumé
Breast cancer (BC) risk is increased among Hodgkin lymphoma (HL) survivors treated with chest radiotherapy. Case-control studies showed a linear radiation dose-response relationship for estimated dose to the breast tumor location. However, these relative risks cannot be used for absolute risk prediction of BC anywhere in the breasts. Furthermore, the independent and joint effects of radiation dose and irradiated volumes are unclear. Therefore, we examined the effects of mean breast dose and various dose-volume parameters on BC risk in HL patients. We conducted a nested case-control study of BC among 5-year HL survivors (173 case patients, 464 matched control patients). Dose-volume histograms were obtained from reconstructed voxel-based 3-dimensional dose distributions. Summary parameters of dose-volume histograms were studied next to mean and median breast dose, Gini index, and the new dose metric mean absolute difference of dose, using categorical and linear excess odds ratio (EOR) models. Interactions between dose-volume parameters and mean dose were also examined. Statistically significant linear dose-response relationships were observed for mean breast dose (EOR per Gy = 0.19, 95% confidence interval [CI] = 0.05 to 1.06) and median dose (EOR/Gy = 0.06, 95% CI = 0.02 to 0.19), with no statistically significant curvature. All metrics except Gini and mean absolute difference were positively correlated with each other. These metrics all showed similar patterns of dose-response that were no longer statistically significant when adjusting for mean dose. No statistically significant modification of the effect of mean dose was observed. Mean breast dose predicts subsequent BC risk in long-term HL survivors.
Sections du résumé
BACKGROUND
Breast cancer (BC) risk is increased among Hodgkin lymphoma (HL) survivors treated with chest radiotherapy. Case-control studies showed a linear radiation dose-response relationship for estimated dose to the breast tumor location. However, these relative risks cannot be used for absolute risk prediction of BC anywhere in the breasts. Furthermore, the independent and joint effects of radiation dose and irradiated volumes are unclear. Therefore, we examined the effects of mean breast dose and various dose-volume parameters on BC risk in HL patients.
METHODS
We conducted a nested case-control study of BC among 5-year HL survivors (173 case patients, 464 matched control patients). Dose-volume histograms were obtained from reconstructed voxel-based 3-dimensional dose distributions. Summary parameters of dose-volume histograms were studied next to mean and median breast dose, Gini index, and the new dose metric mean absolute difference of dose, using categorical and linear excess odds ratio (EOR) models. Interactions between dose-volume parameters and mean dose were also examined.
RESULTS
Statistically significant linear dose-response relationships were observed for mean breast dose (EOR per Gy = 0.19, 95% confidence interval [CI] = 0.05 to 1.06) and median dose (EOR/Gy = 0.06, 95% CI = 0.02 to 0.19), with no statistically significant curvature. All metrics except Gini and mean absolute difference were positively correlated with each other. These metrics all showed similar patterns of dose-response that were no longer statistically significant when adjusting for mean dose. No statistically significant modification of the effect of mean dose was observed.
CONCLUSION
Mean breast dose predicts subsequent BC risk in long-term HL survivors.
Identifiants
pubmed: 35771630
pii: 6623416
doi: 10.1093/jnci/djac125
pmc: PMC9468297
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1270-1278Informations de copyright
© The Author(s) 2022. Published by Oxford University Press.
Références
Br J Hosp Med (Lond). 2019 Oct 2;80(10):574-578
pubmed: 31589515
J Clin Oncol. 2009 Aug 20;27(24):3901-7
pubmed: 19620485
JAMA Pediatr. 2019 Dec 1;173(12):1171-1179
pubmed: 31657853
Pediatr Pulmonol. 2015 Jun;50(6):596-603
pubmed: 24644268
Int J Radiat Oncol Biol Phys. 2016 May 1;95(1):30-36
pubmed: 26684410
Int J Radiat Oncol Biol Phys. 2005 Jul 15;62(4):1090-5
pubmed: 15990013
Clin Transl Radiat Oncol. 2017 Oct 24;7:20-27
pubmed: 29594225
J Clin Oncol. 2014 Jul 20;32(21):2217-23
pubmed: 24752044
Biometrics. 1997 Jun;53(2):767-74
pubmed: 9192463
J Natl Cancer Inst. 2003 Jul 2;95(13):971-80
pubmed: 12837833
Lancet Oncol. 2012 Oct;13(10):1002-10
pubmed: 22921663
Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1510-5
pubmed: 15817357
Radiother Oncol. 2020 Oct;151:33-39
pubmed: 32679305
Blood. 2018 Oct 18;132(16):1635-1646
pubmed: 30108066
J Thorac Dis. 2016 Aug;8(8):2053-60
pubmed: 27621859
J Clin Oncol. 2005 Jan 1;23(1):197-204
pubmed: 15625374
J Clin Oncol. 2020 Dec 10;38(35):4194-4207
pubmed: 33078972
Int J Radiat Oncol Biol Phys. 2014 Jul 15;89(4):854-62
pubmed: 23790512
Int J Radiat Oncol Biol Phys. 2013 Aug 1;86(5):942-8
pubmed: 23726005
Int J Radiat Oncol Biol Phys. 2017 Nov 15;99(4):843-853
pubmed: 28888722
Pract Radiat Oncol. 2019 May;9(3):179-187
pubmed: 30708133
Pract Radiat Oncol. 2017 Jan - Feb;7(1):35-41
pubmed: 27663930
Stat Med. 2021 Nov 20;40(26):5831-5852
pubmed: 34418146
N Engl J Med. 2015 Dec 24;373(26):2499-511
pubmed: 26699166
Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3 Suppl):S155-60
pubmed: 20171512
Breast Cancer Res. 2005;7(1):21-32
pubmed: 15642178
J Clin Oncol. 2019 Jul 1;37(19):1647-1656
pubmed: 31075046
J Radiosurg SBRT. 2018;5(3):229-236
pubmed: 29988301
Ned Tijdschr Geneeskd. 2015;159:A9269
pubmed: 26577382
JAMA. 2003 Jul 23;290(4):465-75
pubmed: 12876089
J Clin Oncol. 2009 Sep 10;27(26):4239-46
pubmed: 19667275
Radiat Res. 2020 Feb;193(2):95-106
pubmed: 31794291